tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ASND Stock Latest News

Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
Press ReleasesAscendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
1d ago
ASND
Ascendis Pharma Provides Update on Vision 3×3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
Press ReleasesAscendis Pharma Provides Update on Vision 3×3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
1M ago
ASND
Ascendis Pharma announces online portal open to request access to TransCon PTH
The FlyAscendis Pharma announces online portal open to request access to TransCon PTH
1M ago
ASND
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
The FlyAscendis Pharma price target raised to $177 from $169 at Wells Fargo
1M ago
TAK
ASND
Ascendis Pharma to initiate TransCon PTH U.S. expanded access program
The FlyAscendis Pharma to initiate TransCon PTH U.S. expanded access program
2M ago
ASND
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
Press ReleasesAscendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
2M ago
ASND
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Press ReleasesAscendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
3M ago
ASND
Ascendis Pharma’s Growth Hormone Shows Promising Results in China
Market NewsAscendis Pharma’s Growth Hormone Shows Promising Results in China
3M ago
ASND
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
Press ReleasesAscendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
3M ago
ASND
BioMarin should rally ‘meaningfully’ after Ascendis data, says Piper Sandler
The FlyBioMarin should rally ‘meaningfully’ after Ascendis data, says Piper Sandler
3M ago
ASND
BMRN
Ascendis Pharma announces topline results from ACcomplisH trial
The FlyAscendis Pharma announces topline results from ACcomplisH trial
3M ago
ASND
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
Press ReleasesOnce-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
3M ago
ASND
Society for Immunotherapy of Cancer to hold a meeting
The FlySociety for Immunotherapy of Cancer to hold a meeting
3M ago
LH
BMY
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022
Press ReleasesDose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022
3M ago
ASND
Ascendis Pharma presents dose-escalation data from transcendIT-101
The FlyAscendis Pharma presents dose-escalation data from transcendIT-101
3M ago
ASND
Society for Immunotherapy of Cancer to hold a meeting
The FlySociety for Immunotherapy of Cancer to hold a meeting
3M ago
LH
BMY
Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential
Stock Analysis & IdeasGoldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential
4M ago
ASND
GOSS
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors
Press ReleasesAscendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors
4M ago
ASND
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
Press ReleasesAscendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism
5M ago
ASND
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
Press ReleasesAscendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
6M ago
ASND